Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.25235
Abstract: No abstract is available for this article. This article is protected by copyright. All rights reserved. read more here.
Keywords: expression lymphoblastic; surface cd19; cd19 cd22; lymphoblastic leukemia ... See more keywords
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Blood Cancer Journal"
DOI: 10.1038/s41408-020-00371-6
Abstract: Dear Editor, CD19 chimeric antigen receptor T cell (CAR-T) therapy has achieved high response rates in patients with relapsed/ refractory acute lymphoblastic leukemia (R/R ALL). However, it was reported that approximately 50% of patients who… read more here.
Keywords: cd19; cd19 cd22; car cells; cell ... See more keywords
Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer investigation"
DOI: 10.1080/07357907.2021.2005798
Abstract: Despite high remission rates following CAR-T cell therapy in B-ALL, relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and… read more here.
Keywords: cd19 cd22; cd22; car; anti tumor ... See more keywords
Targeting CD19-CD22 Aids Younger Patients with ALL.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2020-060
Abstract: In a phase I trial of chimeric antigen receptor T cells targeting CD19 and CD22 in younger patients with relapsed or refractory B-cell acute lymphoblastic leukemia, toxicity was manageable, and five of 12 patients had… read more here.
Keywords: cd19 cd22; younger patients; aids younger; cd22 aids ... See more keywords
Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-113126
Abstract: Introduction: Advances in chimeric antigen receptor (CAR) T cell therapy have yielded complete remission (CR) rates in relapsed/refractory B-ALL (rrB-ALL) of 70-95%. However, disease recurrence after CD19 or CD22 CAR therapy is greater than 50%… read more here.
Keywords: cd19; cd19 cd22; car cells; car ... See more keywords
Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-136866
Abstract: Introduction Multiple issues arise for a wider application of chimeric antigen receptor (CAR) T cell therapy including manufacturing time and antigen escape. Here we report data on an anti-CD19/CD22 dual CAR-T (GC022F) therapy based on… read more here.
Keywords: cd19 cd22; gracell biotechnologies; biotechnologies ltd; cd22 dual ... See more keywords
CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014840
Abstract: Three article in this issue present preclinical data aimed at improving immunotherapeutic approaches for relapsed B- and T-cell acute lymphoblastic leukemia (T-ALL). Chimeric antigen receptor T (CAR-T) cell therapy directed against relapsed T-ALL is hampered… read more here.
Keywords: cell; cd34 cd19; cd19 directed; cd19 cd22 ... See more keywords
A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022016243
Abstract: The bispecific T-cell engager (BiTE) blinatumomab against CD19 and CD3 has emerged as the most successful bispecific antibody (bsAb) to date; however, a significant proportion of patients do not respond to the treatments or eventually… read more here.
Keywords: cd19; cd3; immune escape; cd19 cd22 ... See more keywords
Double CD19/CD22 Chimeric Antigen Receptor-Modified T Cells for the Treatment of Stage IV Relapsed and Refractory Follicular Lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.5154.5154
Abstract: Background: In recent years, frontline rituximab combined with chemotherapy in the treatment of refractory follicular lymphoma (FL) has greatly improved progression free survival. Nevertheless, advanced relapsed/refractory FL is still incurable and novel therapeutics are needed.… read more here.
Keywords: cd19; cd19 cd22; treatment; stage ... See more keywords
Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.954345
Abstract: Background CD22 single and CD19/CD22 bispecific targeted chimeric antigen receptor T (CAR-T) cell therapy are promising immunotherapy modalities for the treatment of hematologic malignancies. The aim of this study was to assess the efficacy and… read more here.
Keywords: cd22; car cell; cd19 cd22;
CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
Sign Up to like & getrecommendations! Published in 2023 at "Oncology Letters"
DOI: 10.3892/ol.2023.13822
Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cells have improved the outcomes of patients with B cell leukemia and lymphoma. However, their applications and positive outcomes remain limited. CAR-T cells are currently restricted to autologous blood as… read more here.
Keywords: car; anti cd19; cd22 bispecific; cd19 cd22 ... See more keywords